Eterna Therapeutics Announces Expansion of Scientific Advisory Board
Eterna Therapeutics (ERNA) has expanded its scientific advisory board with the addition of two experts: Dr. Jerome Zeldis and Dr. Blythe Sather. Dr. Zeldis brings extensive experience in oncology therapy development, having served as Celgene's Chief Medical Officer and held leadership positions at various pharmaceutical companies. He has published 122 peer-reviewed articles and holds 44 U.S. patents.
Dr. Sather, an immunologist specializing in genetic and epigenetic modifications, brings expertise in cell therapy and genetic medicines. Her experience includes work with CRISPR gene editing, CAR-T cell therapies, and leadership roles at companies like Juno Therapeutics and Celgene.
Both advisors will contribute to advancing ERNA-101 for solid tumors and ERNA-102 for autoimmune diseases through preclinical studies.
Eterna Therapeutics (ERNA) ha ampliato il suo comitato consultivo scientifico con l'aggiunta di due esperti: Dr. Jerome Zeldis e Dr. Blythe Sather. Il Dr. Zeldis porta con sé una vasta esperienza nello sviluppo di terapie oncolgiche, avendo ricoperto il ruolo di Chief Medical Officer presso Celgene e posizioni di leadership in diverse aziende farmaceutiche. Ha pubblicato 122 articoli sottoposti a revisione paritaria e possiede 44 brevetti negli Stati Uniti.
La Dr.ssa Sather, un'immunologa specializzata in modifiche genetiche ed epigenetiche, porta competenze nella terapia cellulare e nei medicinali genetici. La sua esperienza include il lavoro con l'editing genetico CRISPR, le terapie CAR-T e ruoli di leadership in aziende come Juno Therapeutics e Celgene.
Entrambi gli esperti contribuiranno all'avanzamento di ERNA-101 per i tumori solidi e ERNA-102 per le malattie autoimmuni attraverso studi preclinici.
Eterna Therapeutics (ERNA) ha ampliado su consejo asesor científico con la incorporación de dos expertos: Dr. Jerome Zeldis y Dr. Blythe Sather. El Dr. Zeldis aporta una amplia experiencia en el desarrollo de terapias oncológicas, habiendo sido Director Médico en Celgene y ocupado posiciones de liderazgo en varias compañías farmacéuticas. Ha publicado 122 artículos revisados por pares y posee 44 patentes en Estados Unidos.
La Dra. Sather, una inmunóloga especializada en modificaciones genéticas y epigenéticas, aporta experiencia en terapia celular y medicamentos genéticos. Su experiencia incluye trabajo con edición genética CRISPR, terapias con células CAR-T y roles de liderazgo en empresas como Juno Therapeutics y Celgene.
Ambos asesores contribuirán al avance de ERNA-101 para tumores sólidos y ERNA-102 para enfermedades autoinmunes a través de estudios preclínicos.
Eterna Therapeutics (ERNA)는 두 명의 전문가인 Dr. Jerome Zeldis와 Dr. Blythe Sather를 추가하여 과학 자문 위원회를 확대했습니다. Zeldis 박사는 Celgene의 최고 의료 책임자로 재직하며 다양한 제약 회사에서 리더십 직책을 맡은 온콜로지 치료 개발 분야에서 폭넓은 경험을 제공합니다. 그는 122개의 동료 평가 저널에 논문을 발표하였으며, 미국 특허를 44개 보유하고 있습니다.
Sather 박사는 유전적 및 후생유전적 변형을 전문으로 하는 면역학자로 세포 치료 및 유전자 의약품 분야의 전문성을 가지고 있습니다. 그녀의 경력에는 CRISPR 유전자 편집, CAR-T 세포 치료 및 Juno Therapeutics 및 Celgene과 같은 기업에서의 리더십 역할이 포함되어 있습니다.
두 자문위원은 ERNA-101을 고형 종양 치료에, ERNA-102를 자가면역 질환 치료에 기여하기 위해 전임상 연구를 통해 발전시키는 데 기여할 것입니다.
Eterna Therapeutics (ERNA) a élargi son conseil consultatif scientifique avec l'ajout de deux experts : Dr. Jerome Zeldis et Dr. Blythe Sather. Le Dr Zeldis apporte une vaste expérience dans le développement de thérapies oncologiques, ayant été directeur médical chez Celgene et occupé des postes de direction dans diverses entreprises pharmaceutiques. Il a publié 122 articles évalués par des pairs et détient 44 brevets aux États-Unis.
La Dr Sather, immunologiste spécialisée dans les modifications génétiques et épigénétiques, apporte son expertise dans les thérapies cellulaires et les médicaments génétiques. Son expérience inclut le travail avec l'édition génomique CRISPR, les thérapies CAR-T et des rôles de direction dans des entreprises comme Juno Therapeutics et Celgene.
Les deux conseillers contribueront à faire progresser ERNA-101 pour les tumeurs solides et ERNA-102 pour les maladies auto-immunes à travers des études précliniques.
Eterna Therapeutics (ERNA) hat seinen wissenschaftlichen Beirat mit der Hinzufügung von zwei Experten erweitert: Dr. Jerome Zeldis und Dr. Blythe Sather. Dr. Zeldis bringt umfassende Erfahrung in der Entwicklung von Onkologie-Therapien mit, da er als Chief Medical Officer bei Celgene tätig war und Führungspositionen in verschiedenen Pharmaunternehmen innehatte. Er hat 122 peer-reviewed Artikel veröffentlicht und besitzt 44 US-Patente.
Dr. Sather, eine Immunologin, die auf genetische und epigenetische Modifikationen spezialisiert ist, bringt Expertise in Zelltherapie und genetischen Arzneimitteln mit. Zu ihren Erfahrungen gehören Arbeiten mit CRISPR-Gentechnologie, CAR-T-Zelltherapien sowie Führungsrollen in Unternehmen wie Juno Therapeutics und Celgene.
Beide Berater werden zur Weiterentwicklung von ERNA-101 für solide Tumoren und ERNA-102 für autoimmune Erkrankungen durch präklinische Studien beitragen.
- Addition of two highly experienced scientific advisors with expertise in cell therapy development
- Dr. Zeldis brings significant industry experience as former Celgene CMO with 122 publications and 44 patents
- Dr. Sather adds valuable expertise in CRISPR gene editing and CAR-T cell therapies
- Both lead products ERNA-101 and ERNA-102 still in preclinical stage
Dr. Jerome Zeldis and Dr. Blythe Sather bring exceptional backgrounds in cell therapy and solid tumors
CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the addition of Jerome Zeldis, M.D., Ph.D., and Blythe Sather, Ph.D., to the company’s scientific advisory board.
"We are fortunate to welcome Dr. Zeldis and Dr. Sather," said Sanjeev Luther, President & CEO of Eterna Therapeutics. "Their extensive experience in developing transformative, high-profile cell therapies for solid tumors has been pivotal in advancing innovative treatments for patients. Their deep expertise will be invaluable as we continue to advance our cell therapies."
Dr. Zeldis brings decades of experience in developing oncology therapies. Coupling his medical expertise with his business acumen, Dr. Zeldis’ unique and critical perspectives allowed for the development and advancement of dozens of cancer therapies. He served as Celgene’s Chief Medical Officer and other leadership roles for over a decade. He also brings experience as an executive or board member at NexImmune, Sorrento Therapeutics, Sandoz Research Institute, Janssen Research Institute, PTC Therapeutics, Soligenix, and NexGel. He has published 122 peer-reviewed articles and holds 44 U.S. patents.
Dr. Sather is an immunologist with a deep expertise in delivering genetic and epigenetic modifications to a variety of cell types to treat disease. Her work spans early discovery to clinical stage programs in both ex vivo cell therapy and in vivo genetic medicines. Her work includes studying the function and trafficking of regulatory T cells, CRISPR-mediated gene editing, lentiviral gene therapies, chimeric antigen receptor (CAR) and T cell receptor next-generation products for solid tumors, and epigenetic modulation to regulate gene expression. She has held research leadership roles at organizations including Juno Therapeutics, Celgene, and Lyell Immunopharma and is currently the head of research at Tune Therapeutics. She brings strong expertise and passion for creating innovative therapeutic solutions for cancer.
With their deep insight and experience in cell therapy, Dr. Zeldis and Dr. Blythe will play a vital role in advancing ERNA-101 in solid tumors and ERNA-102 in autoimmune diseases through their preclinical studies.
About Eterna Therapeutics
Eterna Therapeutics is a publicly traded, preclinical-stage company focused on developing highly innovative, effective, safe off-the-shelf synthetic induced allogenic mesenchymal stem cell (iMSC) therapies. Eterna’s lead product ERNA-101 is an allogeneic pro-inflammatory cytokine (IL-7/IL-15)-secreting iMSC. ERNA-101 capitalizes on the intrinsic tumor-homing and infiltration ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), limiting systemic exposure and potential toxicity while unleashing potent anti-cancer immune responses including enhancement of T-cell anti-tumor activity. The company’s initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer (PROC). The company is also investigating ERNA-102, anti-inflammatory cytokine (IL-10)-secreting iMSCs in inflammatory/auto-immune disorders like rheumatoid arthritis. The company is actively seeking strategic partnerships to co-develop or out-license therapeutic assets and engage with potential collaborators to expand developmental opportunities. For more information, please visit https://www.eternatx.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Eterna's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Eterna's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Eterna's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Eterna does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.
Media & Investor Relations Contact
FAQ
What expertise do the new ERNA scientific advisors bring to the company?
What are the main products in Eterna Therapeutics' (ERNA) pipeline?
How many patents and publications does ERNA's new advisor Dr. Zeldis have?
What is Dr. Blythe Sather's current role outside of ERNA's advisory board?
